A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002)
Y Ikezawa, H Asahina, S Oizumi, M Watanabe… - Cancer chemotherapy …, 2017 - Springer
Purpose A high proportion of patients with wild-type EGFR non-small cell lung cancer
(NSCLC) receive third-line therapy and beyond, with no prospective randomized trials …
(NSCLC) receive third-line therapy and beyond, with no prospective randomized trials …
Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive nonsquamous non-small cell lung cancer …
T Kato, T Seto, M Nishio, K Goto, S Atagi, Y Hosomi… - 2014 - ascopubs.org
8005 Background: Despite the development of EGFR tyrosine kinase inhibitors, median
progression-free survival (PFS) is only about 13 months in patients with EGFR mutation …
progression-free survival (PFS) is only about 13 months in patients with EGFR mutation …
[HTML][HTML] Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer …
N Yamamoto, T Seto, M Nishio, K Goto, I Okamoto… - Lung Cancer, 2021 - Elsevier
Abstract Objectives The JO25567 randomized Phase II study demonstrated a statistically
significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared …
significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared …
Comparison of clinical outcome between gefitinib and erlotinib treatment in patients with non-small cell lung cancer harboring an epidermal growth factor receptor …
SH Lim, JY Lee, JM Sun, JS Ahn, K Park, MJ Ahn - 2013 - ascopubs.org
e19051 Background: Gefitinib and erlotinib are small-molecule kinase inhibitors that inhibit
signaling via EGFR and both agents showed dramatic response rate and prolonged PFS in …
signaling via EGFR and both agents showed dramatic response rate and prolonged PFS in …
Is erlotinib really active after failure of gefitinib in advanced non-small-cell lung cancer patients?
Moreover, among the 104 patients who have obtained a disease control with gefitinib, 42
(40.4%) experienced a disease control (PR or SD) also from erlotinib treatment. Preclinical …
(40.4%) experienced a disease control (PR or SD) also from erlotinib treatment. Preclinical …
Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection
A Hata, N Katakami, H Yoshioka, S Fujita, K Kunimasa… - Lung cancer, 2011 - Elsevier
BACKGROUND: Recent reports have suggested that erlotinib therapy after gefitinib failure
requires optimal patient selection to obtain clinical benefits in relapsed non-small cell lung …
requires optimal patient selection to obtain clinical benefits in relapsed non-small cell lung …
Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations
W Liang, X Wu, W Fang, Y Zhao, Y Yang, Z Hu, C Xue… - PloS one, 2014 - journals.plos.org
Background Several EGFR-tyrosine kinase inhibitors (EGFR-TKIs) including erlotinib,
gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced …
gefitinib, afatinib and icotinib are currently available as treatment for patients with advanced …
A prospective, multicenter phase II trial of low-dose erlotinib as maintenance treatment after platinum doublet chemotherapy for advanced non-small cell lung cancer …
S Hirano, G Naka, Y Takeda, M Iikura… - Chinese Clinical …, 2016 - cco.amegroups.org
Background: Maintenance therapy with full-dose erlotinib for patients with advanced non-
small cell lung cancer (NSCLC) has demonstrated a significant overall survival (OS) benefit …
small cell lung cancer (NSCLC) has demonstrated a significant overall survival (OS) benefit …
[HTML][HTML] Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after …
K Azuma, T Hirashima, N Yamamoto, I Okamoto… - ESMO open, 2016 - Elsevier
Background Patients with epidermal growth factor receptor (EGFR) activation mutation-
positive non-small-cell lung cancer (NSCLC) respond well to EGFR tyrosine kinase …
positive non-small-cell lung cancer (NSCLC) respond well to EGFR tyrosine kinase …
Erlotinib as Second-Line Therapy for Patients with Advanced Non-Small-Cell Lung Cancer and Wild-Type EGFR Tumors
S Vázquez, MJ Villanueva, JL Fírvida… - Journal of …, 2015 - neoplasiaresearch.com
Aim: The objective of the study was to determine the efficacy and safety of erlotinib in second-
line therapy for patients with advanced non-small-cell lung carcinoma (NSCLC) and wild …
line therapy for patients with advanced non-small-cell lung carcinoma (NSCLC) and wild …